PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23430934-1 2012 Dihydropyrimidinase (DHP, EC 3.5.2.2) is the second enzyme of the pyrimidine degradation pathway and a deficiency of this enzyme is responsible for a rare inborn metabolic syndrome characterized by dihydropyrimidinuria. pyrimidine 66-76 dihydropyrimidinase Homo sapiens 0-19 23430934-1 2012 Dihydropyrimidinase (DHP, EC 3.5.2.2) is the second enzyme of the pyrimidine degradation pathway and a deficiency of this enzyme is responsible for a rare inborn metabolic syndrome characterized by dihydropyrimidinuria. pyrimidine 66-76 dihydropyrimidinase Homo sapiens 21-24 18600547-1 2008 Dihydropyrimidinase (DHP) deficiency is an inborn error of the pyrimidine degradation pathway, affecting the hydrolytic ring opening of the dihydropyrimidines. pyrimidine 63-73 dihydropyrimidinase Homo sapiens 0-19 19571472-3 2009 Enzyme deficiency involved in pyrimidine degradation, such as Dihydropyrimidine dehydrogenase (DPD) and Dihydropyrimidinase (DHP), has been reported with convulsion or autism as symptoms, but many asymptomatic cases are also reported. pyrimidine 30-40 dihydropyrimidinase Homo sapiens 104-123 20362666-1 2010 Dihydropyrimidinase (DHP) is the second enzyme of the pyrimidine degradation pathway and catalyses the ring opening of 5,6-dihydrouracil and 5,6-dihydrothymine. pyrimidine 54-64 dihydropyrimidinase Homo sapiens 0-19 20362666-1 2010 Dihydropyrimidinase (DHP) is the second enzyme of the pyrimidine degradation pathway and catalyses the ring opening of 5,6-dihydrouracil and 5,6-dihydrothymine. pyrimidine 54-64 dihydropyrimidinase Homo sapiens 21-24 19571472-3 2009 Enzyme deficiency involved in pyrimidine degradation, such as Dihydropyrimidine dehydrogenase (DPD) and Dihydropyrimidinase (DHP), has been reported with convulsion or autism as symptoms, but many asymptomatic cases are also reported. pyrimidine 30-40 dihydropyrimidinase Homo sapiens 125-128 18600547-1 2008 Dihydropyrimidinase (DHP) deficiency is an inborn error of the pyrimidine degradation pathway, affecting the hydrolytic ring opening of the dihydropyrimidines. pyrimidine 63-73 dihydropyrimidinase Homo sapiens 21-24 12626710-1 2003 Slime mold, plant and insect dihydropyrimidine amidohydrolases (DHPases, EC 3.5.2.2), which catalyze the second step of pyrimidine and several anti-cancer drug degradations, were cloned and shown to functionally replace a defective DHPase enzyme in the yeast Saccharomyces kluyveri. pyrimidine 36-46 dihydropyrimidinase Homo sapiens 64-70 17383919-1 2007 Dihydropyrimidinase (DHP) is the second enzyme of the pyrimidine degradation pathway and it catalyses the ring opening of 5,6-dihydrouracil and 5,6-dihydrothymine to N-carbamyl-beta-alanine and N-carbamyl-beta-aminoisobutyric acid, respectively. pyrimidine 54-64 dihydropyrimidinase Homo sapiens 0-19 17383919-1 2007 Dihydropyrimidinase (DHP) is the second enzyme of the pyrimidine degradation pathway and it catalyses the ring opening of 5,6-dihydrouracil and 5,6-dihydrothymine to N-carbamyl-beta-alanine and N-carbamyl-beta-aminoisobutyric acid, respectively. pyrimidine 54-64 dihydropyrimidinase Homo sapiens 21-24 10656811-16 2000 Apparently, dihydrouracil and DHPase represent an important regulatory checkpoint of the pyrimidine catabolic pathway in S. kluyveri. pyrimidine 89-99 dihydropyrimidinase Homo sapiens 30-36 29054612-1 2017 Dihydropyrimidinase (DHP) is the second enzyme of the pyrimidine degradation pathway and catalyzes the ring opening of 5,6-dihydrouracil and 5,6-dihydrothymine. pyrimidine 54-64 dihydropyrimidinase Homo sapiens 0-19 8448846-3 1993 Applications of thin-layer chromatography, high-performance liquid chromatography, and conventional cation-exchange amino acid analysis lead to detection of various defects in pyrimidine degradation, including the recently described deficiencies of dihydropyrimidine dehydrogenase and dihydropyrimidinase. pyrimidine 176-186 dihydropyrimidinase Homo sapiens 285-304 7765578-9 1994 It has been suggested that D-amino acid production from DL-5-substituted hydantoin involves the action of a series of enzymes involved in pyrimidine degradation, namely amide-ring opening enzyme, dihydropyrimidinase, and N-carbamoylamide hydrolyzing enzyme, beta-ureidopropionase. pyrimidine 138-148 dihydropyrimidinase Homo sapiens 196-215 3931905-1 1985 Enzymes of the pyrimidine base catabolism, dihydrouracil dehydrogenase (EC 1.3.1.2), dihydropyrimidinase (EC 3.5.2.2), and beta-ureidopropionase (EC 3.5.1.6) were compared in the cytosolic extract of several normal and neoplastic human tissues. pyrimidine 15-25 dihydropyrimidinase Homo sapiens 85-104 3931905-3 1985 Substrate inhibition, hysteresis, allosterism, and the lack of dihydropyrimidinase are pointed out as special problems in assaying enzymes of pyrimidine degradation. pyrimidine 142-152 dihydropyrimidinase Homo sapiens 63-82 29054612-1 2017 Dihydropyrimidinase (DHP) is the second enzyme of the pyrimidine degradation pathway and catalyzes the ring opening of 5,6-dihydrouracil and 5,6-dihydrothymine. pyrimidine 54-64 dihydropyrimidinase Homo sapiens 21-24 26609109-4 2016 In addition, dihydropyrimidine dehydrogenase (DPYD) and other important pyrimidine-related genes: DPYS, AK9, CAD, CANT1, ENTPD1, NME6, NT5C1A, POLE, POLQ, POLR3B, PRIM2, REV3L, and UPP2 are significantly enriched in somatic mutations relative to the background mutation rate. pyrimidine 20-30 dihydropyrimidinase Homo sapiens 98-102 28642038-1 2017 Dihydropyrimidinase (DHP, EC 3.5.2.2), encoded by the gene DPYS, is the second enzyme in the catabolic pathway of pyrimidine and of fluoropyrimidine drugs such as 5-fluorouracil, which are commonly used in anticancer treatment; DHP catalyzes the hydrolytic ring opening of dihydrouracil and dihydro-5-fluorouracil. pyrimidine 114-124 dihydropyrimidinase Homo sapiens 0-19 28642038-1 2017 Dihydropyrimidinase (DHP, EC 3.5.2.2), encoded by the gene DPYS, is the second enzyme in the catabolic pathway of pyrimidine and of fluoropyrimidine drugs such as 5-fluorouracil, which are commonly used in anticancer treatment; DHP catalyzes the hydrolytic ring opening of dihydrouracil and dihydro-5-fluorouracil. pyrimidine 114-124 dihydropyrimidinase Homo sapiens 21-24 28642038-1 2017 Dihydropyrimidinase (DHP, EC 3.5.2.2), encoded by the gene DPYS, is the second enzyme in the catabolic pathway of pyrimidine and of fluoropyrimidine drugs such as 5-fluorouracil, which are commonly used in anticancer treatment; DHP catalyzes the hydrolytic ring opening of dihydrouracil and dihydro-5-fluorouracil. pyrimidine 114-124 dihydropyrimidinase Homo sapiens 59-63 28642038-1 2017 Dihydropyrimidinase (DHP, EC 3.5.2.2), encoded by the gene DPYS, is the second enzyme in the catabolic pathway of pyrimidine and of fluoropyrimidine drugs such as 5-fluorouracil, which are commonly used in anticancer treatment; DHP catalyzes the hydrolytic ring opening of dihydrouracil and dihydro-5-fluorouracil. pyrimidine 114-124 dihydropyrimidinase Homo sapiens 228-231 25066213-4 2014 Thirteen variants in the pyrimidine metabolism genes, DPYD, DPYS, PPAT, and TYMS, also interacted significantly with folate in a multivariant analysis (corrected p = 9.9 x 10-6) but collectively explained only 0.2% of OC risk. pyrimidine 25-35 dihydropyrimidinase Homo sapiens 60-64